CRB-701 (CSPC)

About Corbus Pharmaceuticals

Founded in 2009, Corbus Pharmaceuticals is a publicly-traded company focused on advancing targeted treatments for oncology and metabolic diseases. Its strategy leverages deep biological insight into mechanisms like Nectin-4 in cancer and peripheral CB1 receptors in obesity. The company has progressed its lead oncology asset, CRB-701, into dose optimization studies and recently reported positive Phase 1a safety data for its obesity candidate, CRB-913, positioning it for continued clinical development.

Therapeutic Areas